Shanghai Hutchison Pharmaceuticals Products

Updated:2016-02-05 (chinadaily.com.cn)

Heart-protecting Musk Pill

麝香保心丸_调整大小.jpg

The heart-protecting musk pill is a traditional Chinese medication with independent intellectual property rights, solely owned by Shanghai Hutchison Pharmaceuticals. It is safe, convenient, cheap, and has a definite clinical effect; it is a commonly used medicine for treating coronary heart disease and angor pectoris. It is listed in national essential drugs, medicare catalog I, national low-price drugs, and national secret technologies. Its original innovations have won 10 patents and have been published in more than 800 papers, 50 of which were published on SCI, and one of which was published in the leading journal Science. It was awarded first prize of the Shanghai Science and Technology Progress Awards in 2011, and named as a "Key New Product" by the Ministry of Science and Technology in 2014.

Heart-protecting musk has been clinically applied for 32 years since its launch in 1983. It achieved revenue of 1.2 billion yuan in 2015. With a weight of 22.5mg and diameter of 2.85mm, the medical fee per day costs only 2 yuan; but it is the only solid preparation of traditional Chinese medicine in Shanghai to achieve annual revenue of over 1 billion yuan. The small pill has made a great contribution to the treatment of cardiovascular diseases and economic development in Shanghai.

Danning Tablets

胆宁片_调整大小.jpg

Danning tablets are the first state-level new drug in Shanghai. It is a traditional Chinese medication with independent intellectual property rights, solely owned by Shanghai Hutchison Pharmaceuticals. It is listed in traditional Chinese medicine protection categories and national medicare category II. It is commonly used for treating chronic cholecystitis and gallstones. Its technological standard was included in "Chinese Pharmacopoeia" in 2005. It owns 3 patents and was listed in "Shanghai Innovative Products". It was among the “Shanghai Top 10 Excellent Patent Products” in 2009. It has achieved annual revenue of 100 million yuan since 2014, and become an important Chinese medicine for treating chronic cholecystitis and gallstones.

8.03K